Crossover trial in 54 adults with IgA nephropathy on maximal RASi and SGLT2i: atrasentan reduced UPCR at week 12 vs placebo (geometric mean difference -25.3%; 95% CI -36.8 to -11.7); fluid retention was uncommon.
RCTn = 54
Heerspink et al. Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial